Iradimed Book Value Per Share Growth & History (IRMD)
Iradimed's book value per share was $7.40 for fiscal 2025.
View full Iradimed company overviewIradimed annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.40 | $0.57 | +8.37% |
| 2024 | 2024-12-31 | $6.83 | $1.19 | +21.09% |
| 2023 | 2023-12-31 | $5.64 | -$0.21 | −3.59% |
| 2022 | 2022-12-31 | $5.85 | $0.10 | +1.70% |
| 2021 | 2021-12-31 | $5.75 | $0.77 | +15.37% |
| 2020 | 2020-12-31 | $4.99 | $0.27 | +5.68% |
| 2019 | 2019-12-31 | $4.72 | $0.90 | +23.63% |
| 2018 | 2018-12-31 | $3.82 | $0.71 | +22.83% |
| 2017 | 2017-12-31 | $3.11 | $0.13 | +4.50% |
| 2016 | 2016-12-31 | $2.97 | $0.12 | +4.08% |
| 2015 | 2015-12-31 | $2.86 | $0.93 | +47.93% |
| 2014 | 2014-12-31 | $1.93 | $1.16 | +149.36% |
| 2013 | 2013-12-31 | $0.77 | — | — |
Iradimed quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $7.96 | $0.54 | +7.33% |
| Q1 2026 | 2026-03-31 | $7.71 | $0.62 | +8.81% |
| Q4 2025 | 2025-12-31 | $7.40 | $0.57 | +8.37% |
| Q3 2025 | 2025-09-30 | $7.73 | $1.15 | +17.41% |
| Q2 2025 | 2025-06-30 | $7.41 | $1.12 | +17.89% |
| Q1 2025 | 2025-03-31 | $7.08 | $1.07 | +17.83% |
| Q4 2024 | 2024-12-31 | $6.83 | $1.19 | +21.09% |
| Q3 2024 | 2024-09-30 | $6.59 | $0.67 | +11.30% |
| Q2 2024 | 2024-06-30 | $6.29 | $0.81 | +14.86% |
| Q1 2024 | 2024-03-31 | $6.01 | $0.90 | +17.66% |
| Q4 2023 | 2023-12-31 | $5.64 | -$0.21 | −3.59% |
| Q3 2023 | 2023-09-30 | $5.92 | $0.36 | +6.52% |
| Q2 2023 | 2023-06-30 | $5.47 | $0.23 | +4.36% |
| Q1 2023 | 2023-03-31 | $5.11 | $0.13 | +2.59% |
| Q4 2022 | 2022-12-31 | $5.85 | $0.10 | +1.70% |
| Q3 2022 | 2022-09-30 | $5.55 | $0.05 | +0.97% |
| Q2 2022 | 2022-06-30 | $5.25 | -$0.02 | −0.44% |
| Q1 2022 | 2022-03-31 | $4.98 | -$0.14 | −2.80% |
| Q4 2021 | 2021-12-31 | $5.75 | $0.77 | +15.37% |
| Q3 2021 | 2021-09-30 | $5.50 | $0.55 | +11.17% |
| Q2 2021 | 2021-06-30 | $5.27 | $0.48 | +10.13% |
| Q1 2021 | 2021-03-31 | $5.12 | $0.27 | +5.63% |
| Q4 2020 | 2020-12-31 | $4.99 | $0.27 | +5.68% |
| Q3 2020 | 2020-09-30 | $4.95 | $0.42 | +9.27% |
| Q2 2020 | 2020-06-30 | $4.78 | $0.57 | +13.63% |
| Q1 2020 | 2020-03-31 | $4.85 | $0.84 | +21.07% |
| Q4 2019 | 2019-12-31 | $4.72 | $0.90 | +23.63% |
| Q3 2019 | 2019-09-30 | $4.53 | $0.86 | +23.51% |
| Q2 2019 | 2019-06-30 | $4.21 | $0.82 | +24.19% |
| Q1 2019 | 2019-03-31 | $4.01 | $0.78 | +24.29% |
| Q4 2018 | 2018-12-31 | $3.82 | $0.71 | +22.83% |
| Q3 2018 | 2018-09-30 | $3.67 | $0.62 | +20.41% |
| Q2 2018 | 2018-06-30 | $3.39 | $0.43 | +14.65% |
| Q1 2018 | 2018-03-31 | $3.22 | $0.24 | +8.19% |
| Q4 2017 | 2017-12-31 | $3.11 | $0.13 | +4.50% |
| Q3 2017 | 2017-09-30 | $3.05 | $0.18 | +6.45% |
| Q2 2017 | 2017-06-30 | $2.96 | $0.29 | +10.82% |
| Q1 2017 | 2017-03-31 | $2.98 | $0.30 | +11.19% |
| Q4 2016 | 2016-12-31 | $2.97 | $0.12 | +4.08% |
| Q3 2016 | 2016-09-30 | $2.86 | $0.32 | +12.63% |
| Q2 2016 | 2016-06-30 | $2.67 | $0.38 | +16.76% |
| Q1 2016 | 2016-03-31 | $2.68 | $0.59 | +28.02% |
| Q4 2015 | 2015-12-31 | $2.86 | $0.93 | +47.93% |
| Q3 2015 | 2015-09-30 | $2.54 | $0.66 | +35.09% |
| Q2 2015 | 2015-06-30 | $2.29 | $1.24 | +119.16% |
| Q1 2015 | 2015-03-31 | $2.09 | — | — |
| Q4 2014 | 2014-12-31 | $1.93 | $1.16 | +149.36% |
| Q3 2014 | 2014-09-30 | $1.88 | — | — |
| Q2 2014 | 2014-06-30 | $1.04 | — | — |
| Q4 2013 | 2013-12-31 | $0.77 | — | — |
Iradimed book value per share trends
Over the last five fiscal years, Iradimed's book value per share increased from $4.99 to $7.40, a change of $2.42. The latest reported quarter, Q2 2026, shows $7.96.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Iradimed source filings ↗